Tamtam Try Tamtam free
Tufts Medicine logo

Tufts Medicine account plan

Health care provider network

At a glance

Tufts Medicine is a Boston-area nonprofit health system of four acute hospitals, home care and an ACO network, with FY2025 revenue of $2,967.3 million.

Tufts Medicine, Inc. is the Boston-area nonprofit parent of Tufts Medical Center, Lowell General Hospital (Circle Health), MelroseWakefield Healthcare (two acute hospitals), Tufts Medicine Care at Home, the Tufts Medicine Integrated Network and a Cayman captive insurer. In FY2025 (year to September 30, 2025) total revenue was $2,967.3 million, up from $2,639.3 million, and the loss from operations narrowed to $58.6 million from $250.7 million. Patient service revenue of $2,342.4 million came 38% from Medicare, 39% from managed care and 18% from Medicaid. The system is in a financial turnaround on a thin balance sheet, with long-term debt of $894.8 million against net assets of $190.4 million.

Business units

Strategic priorities

Financial turnaround
The board chair says the system is entering the next phase of its financial turnaround; the FY2025 deficiency narrowed to $51.6 million from $214.0 million.
Throughput and clinical growth
The CFO named access, length of stay and growth of key clinical programs as next priorities in July 2025.
Payer mix and ambulatory care
Management aims to shift payer mix and expand the ambulatory setting; outpatient grew to 41% of patient service revenue in FY2025 from 38%.
Rebuilding the balance sheet
The plan includes monetizing non-strategic assets; a 30-year energy-as-a-service deal on chilled water and steam infrastructure brings about $365 million at financial close in February 2026.
Value-based care
The CFO wants to bend the cost curve and move to value-based care, building on TMIN's risk contracts.

Latest results

For the nine months to June 30, 2026 (fiscal Q3 2026), the CHIA filing shows total operating revenue of $2,468.9 million against $2,278.9 million a year earlier. The system operating loss was $79.5 million, an operating margin of -3.2% against -2.2% in the prior year-to-date, and the deficit of revenue over expenses widened to $62.8 million from $47.0 million. Tufts Medical Center improved to a 3.9% margin while MelroseWakefield fell to -10.1% and Lowell General slipped to 2.0%. Cash stood at $62.1 million and long-term debt at $914.5 million at June 30, 2026, with debt service coverage of 0.56.

Investments and deals

Bond refinancing
In November 2025 the 8.50% Series E bonds and two smaller series were refinanced into Series F ($30.2 million, 5.50%) and Series G ($154.1 million).
Energy-as-a-service deal
A 30-year energy-as-a-service agreement on chilled water and steam infrastructure brings about $365 million at financial close in February 2026.
Lab outreach sale
Lab outreach testing was sold to Labcorp, involving 600 roles.
Pharmacy growth
Specialty and retail pharmacy revenue grew to $355.3 million in FY2025 from $244.2 million.

Challenges and risks

Operating losses
The system lost $79.5 million at the operating level in the nine months to June 30, 2026, with a -3.2% margin.
Thin balance sheet
Cash was $62.1 million and long-term debt to capitalization 0.92 at June 30, 2026; capex was cut to $23.6 million in FY2025 from $51.5 million.
Loss-making physician organizations and MelroseWakefield
The Tufts Medical Center Physician Organization had a -22.8% margin and MelroseWakefield a -10.1% margin in the nine months to June 30, 2026.
Leadership transition
CEO Mike Dandorph and CFO Andrew Devoe are stepping down; a national CFO search is under way.
Cost inflation and payer denials
The CFO cited post-COVID cost inflation and payer denials, 97-99% of which are overturned on appeal; FEMA COVID grant revenue fell to $10.9 million from $57.4 million.

What leadership says

“we have turned the corner, and we're starting to rebuild the balance sheet”

Andrew DeVoe, Executive Vice President and CFO · Becker's CFO + Revenue Cycle Podcast, July 9, 2025

“While important work remains ahead, we have generated significant momentum and are entering the next phase of our financial turnaround with greater focus, discipline and purpose”

Phil Lembo, Board Chair · Healthcare Dive, August 6, 2026, on the CEO and CFO stepping down

“Our focus remains unchanged: serving our patients and communities, supporting our people, strengthening our financial position and continuing to advance Tufts Medicine's mission to empower people to live their best lives”

Phil Okala, COO and incoming CEO · Healthcare Dive, August 6, 2026

Where a supplier can help

Revenue cycle and denials
Tied to the payer-denials challenge and the turnaround priority: revenue cycle, pre-authorization and denial-management vendors, including contingency-based offers the CFO has used, address a lever management names.
Throughput and capacity
Tied to the throughput priority: patient-flow, scheduling and length-of-stay tools support access and clinical program growth.
Ambulatory expansion
Tied to the ambulatory care priority: outpatient facilities, digital front door and ambulatory operations partners fit the shift away from inpatient care.
Value-based care analytics
Tied to the value-based care priority and TMIN's risk contracts: population-health and care-coordination analytics support shared-savings performance.
Cost and asset monetization
Tied to the thin balance sheet: suppliers offering capital-light or as-a-service models, like the energy deal, match the push to monetize non-strategic assets.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Tufts Medicine?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Tufts Medicine

What is Tufts Medicine?

A Boston-area nonprofit health system that owns Tufts Medical Center, Lowell General Hospital, MelroseWakefield Healthcare, a home care and hospice business, an ACO network and a captive insurer.

What is Tufts Medicine's revenue?

Total revenue was $2,967.3 million in FY2025 (year to September 30, 2025). Operating revenue was $2,468.9 million for the nine months to June 30, 2026.

Who leads Tufts Medicine?

Mike Dandorph is CEO through the end of fiscal 2026, after which COO Phil Okala becomes chief executive. Phil Lembo chairs the board.

Is Tufts Medicine profitable?

No. It reported a loss from operations of $58.6 million in FY2025 and an operating loss of $79.5 million in the nine months to June 30, 2026, though Tufts Medical Center itself is profitable.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)